Artelo Biosciences, Inc. (ARTL)

NASDAQ: ARTL · IEX Real-Time Price · USD
2.68
+0.12 (4.69%)
Dec 5, 2022 3:26 PM EST - Market open
4.69%
Market Cap 7.31M
Revenue (ttm) n/a
Net Income (ttm) -10.78M
Shares Out 2.85M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Aug 10, 2022
Volume 45,879
Open 2.59
Previous Close 2.56
Day's Range 2.59 - 2.79
52-Week Range 2.38 - 11.07
Beta 1.17
Analysts Buy
Price Target 42.50 (+1,485.8%)
Earnings Date Nov 11, 2022

About ARTL

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for pr... [Read more]

Industry Pharmaceuticals
Founded 2011
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ARTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ARTL stock is "Buy." The 12-month stock price forecast is 42.5, which is an increase of 1,485.82% from the latest price.

Price Target
$42.5
(1,485.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Enrollment of Phase 2a CAReS Study Expected to Commence Near Year-End

3 weeks ago - GlobeNewsWire

Artelo Biosciences to Present at The LD Micro Main Event XV

Solana Beach, California--(Newsfile Corp. - October 18, 2022) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

1 month ago - Newsfile Corp

Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th

SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...

2 months ago - GlobeNewsWire

Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...

2 months ago - GlobeNewsWire

Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study

Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.

3 months ago - Zacks Investment Research

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Recently Published Findings Support Further Development in Anxiety-Related Disorders Recently Published Findings Support Further Development in Anxiety-Related Disorders

3 months ago - GlobeNewsWire

Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort

3 months ago - GlobeNewsWire

Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Tre...

Initiates Fourth Cohort at a 650-Microgram Dose with Data Expected in Q4 2022 Initiates Fourth Cohort at a 650-Microgram Dose with Data Expected in Q4 2022

4 months ago - GlobeNewsWire

Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemot...

Presentation delivered by Professor Saoirse O'Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th Presentation delivered by Professor Saoirse O'Sullivan at the 32nd Annual...

5 months ago - GlobeNewsWire

Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland

SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat...

5 months ago - GlobeNewsWire

Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th

SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) --   Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage pharmaceutical company developing therapeutics that modulat...

6 months ago - GlobeNewsWire

Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th

SOLANA BEACH, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate l...

6 months ago - GlobeNewsWire

Artelo Biosciences to Present at MicroCap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-sign...

6 months ago - Accesswire

Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

$23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and Operations Into Second Half of 2023

6 months ago - GlobeNewsWire

Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York

Solana Beach, California--(Newsfile Corp. - April 26, 2022) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathw...

7 months ago - Newsfile Corp

Artelo Shares Jump On Favorable Preclinical Data In Cancer-Related Muscle-Wasting Syndrome

Artelo Biosciences Inc (NASDAQ: ARTL) says its ART27.13 shows promising preclinical results in protecting human muscle cells from cancer-induced muscle degeneration (cachexia) via a CB2 mediated mechani...

7 months ago - Benzinga

Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia

New Research from Trinity College Dublin Indicates Broader Therapeutic Potential for ART27.13 New Research from Trinity College Dublin Indicates Broader Therapeutic Potential for ART27.13

7 months ago - GlobeNewsWire

Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protei...

New Potential Uses of ART26.12 for Treating Tumors New Potential Uses of ART26.12 for Treating Tumors

8 months ago - GlobeNewsWire

Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-...

SOLANA BEACH, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, ...

8 months ago - GlobeNewsWire

Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provi...

Reports $25.6 Million in Cash and Marketable Securities as of December 31, 2021, Expected to Support Operations Into Second Half of 2023 Reports $25.6 Million in Cash and Marketable Securities as of Dec...

8 months ago - GlobeNewsWire

Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprie...

SOLANA BEACH, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatm...

9 months ago - GlobeNewsWire

Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update

Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022

10 months ago - GlobeNewsWire

Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Ki...

SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom's Home Office has classified the Company's lead clinical cannabinoid, AR...

10 months ago - GlobeNewsWire

Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual ...

Artelo CEO also providing corporate outlook for 2022 at the H.C. Wainwright Conference Artelo CEO also providing corporate outlook for 2022 at the H.C. Wainwright Conference

10 months ago - GlobeNewsWire

Is Artelo Biosciences, Inc. (ARTL) Stock Outpacing Its Medical Peers This Year?

Here is how Artelo Biosciences, Inc. (ARTL) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.

10 months ago - Zacks Investment Research